# An Observational Study of Upadacitinib to Assess Change in Disease Activity in Canadian Adult Participants With Moderate-to-Severe Atopic Dermatitis Who Are Inadequate Responders To or Discontinuing Dupilumab

> **NCT05394792** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 111 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05394792
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-01
- **Primary completion:** 2024-08-15
- **Final completion:** 2024-08-15
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05394792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05394792, "An Observational Study of Upadacitinib to Assess Change in Disease Activity in Canadian Adult Participants With Moderate-to-Severe Atopic Dermatitis Who Are Inadequate Responders To or Discontinuing Dupilumab". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05394792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*